Read our February issue! Featuring Oropouche virus in Brazil, mosquito-disseminated pyriproxyfen to control dengue, and TB diagnostics in children https://t.co/tYWGmdv8QI

Trachoma is the leading infectious cause of blindness worldwide. In a new Seminar, Esmael Habtamu & colleagues provide an overview of the key clinical and public health features of trachoma. Explore now ➡️ https://t.co/BzPY2FDWa2

☀️ On the cover of @TheLancetInfDis June issue in time for European arbovirus season, the @PREPARE_EUROPE MERMAIDS-Arbo doublebill of papers with commentary now in print - thank you! 🦟 Full issue: https://t.co/5WSJyjiRVP 🤒 Clinical outcomes: https://t.co/5OIX2g6NEX 🦠

In @TheLancetInfDis, MSF highlighted the urgent need for a ring vaccination strategy to curb the cholera outbreak in DRC and neighbouring countries, worsened by ongoing conflict. #Cholera #GlobalHealth #DRC 💉 https://t.co/NFQHPLxtuw

A study in @TheLancetInfDis confirmed the safety & efficacy of single low-dose primaquine in reducing malaria transmission in young children & could support global #malaria elimination efforts & limit the spread of drug resistant #malaria https://t.co/6r0gpAL2sh @TropMedOxford

While little is known about the mysterious #Oropouche virus in Latin America, a number of deaths have been reported along with impacts on unborn babies. A #CharitéBerlin study has discovered that the pathogen is more widespread than previously thought. https://t.co/aGI7DFF03v

Now, there is a 2024 WHO Bacterial Priority Pathogens List 🆕 An article in @TheLancetInfDis details the processes involved in this important revision ⤵️

1/5 🔥 Hot off the press — PAXLC trial results now in @TheLancetInfDis （🇯🇵日本語解説付き） After 3 years of dedicated work, we’re proud to share results from PAX LC: a fully decentralized, double-blind, placebo-controlled, FDA-authorized Phase 2 trial of Paxlovid

We were so happy to partner with participants on this decentralized, technology-enabled trial. Innovative way to do trials. I just wish the result had been better for patients. @VirusesImmunity @YaleMed @yalediscovers @TheLancetInfDis

We are hiring a Deputy Editor for The Lancet Regional Health – Southeast Asia Find out more about the role here https://t.co/xqjzcdxZvw @TheLancet @GKangInd @doctorsoumya @WHOSEARO @AnuragAgrawalMD @swarup1972 @vivekkute @combatstrokeSL @lakshmivijayku1

Out now in @TheLancetInfDis our #SEMVAc study demonstrates that the MVA-BN vaccine (Imvanex/Jynneos) is safe & effective against #mpox, but a single dose does not sufficiently protect people living with #HIV. Thank you @EMA_News for support. https://t.co/nKoSKnqLFz

RESISTANCE IN TB AND HIV: Article we just wrote for the @TheLancetInfDis on a consequence of HIV global funding cuts that has not been discussed much -the development of drug resistance in HIV and TB https://t.co/jNnsu7A2Us

Well done to my sister @AnjaSaso on her excellent RCT just published in @TheLancetInfDis looking at effect of #pertussis vaccine in pregnancy Huge amount of work at @mrcunitgambia 🇬🇲 Proud brother! https://t.co/8y9p7OYU9V

Delighted to share my latest clinical case report published in @TheLancetInfDis from Fudan University, highlighting a case of mistaken identity—sinusitis mimicking meningioma! Thanks to @FadenLab from @MassEyeAndEar @Harvard, the co-first author, for his invaluable guidance

🆕The absence of essential diagnostic & therapeutic tools is a crucial barrier to Zika virus preparedness & response. A @TheLancetInfDis & Lancet Microbe Series outlines a comprehensive strategy to advance research, policy, & investment to address this: https://t.co/CuukovYuMB

Very pleased to share our latest paper in @TheLancetInfDis. This paper considers the complex issues of antimicrobials at the end-of-life, including nonclinical factors that must be navigated in the dying process. Thanks to @BillyRosaPhD for leading this! https://t.co/5BjqIHHmG0

With cholera resurging in recent years, this letter by @SecGTFCC @TheLancetInfDis highlights the crucial principle of adaptive surveillance. It stresses that surveillance must be tailored to different epidemiological contexts, as outlined in their guidance https://t.co/ThOPUzJXNX

Cholera has skyrocketed globally in recent years, linked to factors such as conflict, displacement, and climate change. A lack of political commitment & investment in controlling cases has also contributed to its resurgence. Read more in the latest news piece from

In this editorial in @TheLancetInfDis with @ACasadevall1 , we show how SARS-CoV-2 evolution once again defeated an anti-Spike mAb (#sipavibart / #AZD3152) before it reached the marked. https://t.co/eiEHAfELMG @bjarijn @ShohamTxID @jhDavidSullivan @manuelenicastri @hueso_thomas

💊Very happy to share our paper in @TheLancetInfDis on doxypep: hopes and fears for implementation . 😍This is a joint effort with @GilmoreJNurse ; Manik Kohli; @EdFTMxxx ; @benvyle; and Laia Ventura 👉Access here: https://t.co/WTQSMW8eWp

Europe needs a sustainably funded influenza research and response network - especially in the light of H5N1 and current developments in the US. Read our commentary in The Lancet ID: https://t.co/pMcpsAQ6Le With @wendybarclay11, @MarionKoopmans and many other colleagues.